Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOND-3: Irinotecan, Cetuximab, and Bevacizumab in mCRC
NCT02292758Phase 2Completed
- Sponsor
- Academic and Community Cancer Research United
- Start
- Dec 2014
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Academic and Community Cancer Research United. Started Dec 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02292758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292758.